RLYB
Rallybio Corp

624
Mkt Cap
$39.81M
Volume
103,895.00
52W High
$7.78
52W Low
$1.76
PE Ratio
-2.95
RLYB Fundamentals
Price
$7.54
Prev Close
$6.80
Open
$6.78
50D MA
$5.43
Beta
1.45
Avg. Volume
18,111.44
EPS (Annual)
-$10.61
P/B
0.63
Rev/Employee
$25,440.00
$23.55
Loading...
Loading...
News
all
press releases
Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026
Rallybio reports strong Phase 1 results for RLYB116, showing full immune pathway control with good safety and Phase 2 plans ahead.read more...
Benzinga·13d ago
News Placeholder
More News
News Placeholder
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced...
Business Wire·13d ago
News Placeholder
Rallybio Announces Reverse Stock Split of Common Stock
Rallybio Corporation (Nasdaq: RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybios Amended and...
Business Wire·26d ago
News Placeholder
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported...
Business Wire·4mo ago
News Placeholder
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
Zacks·8mo ago
<
...
1
>

Latest RLYB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.